» Articles » PMID: 10754501

A Possible Divergent Role for the Oestrogen Receptor Alpha and Beta Subtypes in Clinical Breast Cancer

Overview
Journal Int J Cancer
Specialty Oncology
Date 2001 Feb 7
PMID 10754501
Citations 10
Authors
Affiliations
Soon will be listed here.
Abstract

We have examined the relative levels of oestrogen receptor beta (ERbeta) mRNA in 94 breast cancer specimens using a semi-quantitative RT-PCR procedure. We correlated its expression with ERalpha and various clinical, pathological and biochemical features of the disease. The level of ERbeta mRNA expression in these samples was found to be much lower than ERalpha. Although ERalpha mRNA species were found to be most frequently associated with histological grade I and II tumours, displaying tubular differentiation, low grades of nuclear pleomorphism and low mitotic activity, such features were not characteristic of ERbeta positive samples. Indeed, application of the Spearman rank correlation test revealed that there was an inverse association between ERbeta normalised levels and ERalpha protein HScore. Also ERbeta mRNA positive cancers were more frequently EGFR protein positive than their negative counterparts (p = 0.016), a feature normally associated with endocrine-insensitive disease. Our data suggest that although ERbeta levels are most likely lower than ERalpha, they may influence the biological behaviour of breast cancers containing low levels of ERalpha.

Citing Articles

ERβ Isoforms Have Differential Clinical Significance in Breast Cancer Subtypes and Subgroups.

Choi Y, Kim H, Pollack S Curr Issues Mol Biol. 2022; 44(4):1564-1586.

PMID: 35723365 PMC: 9164084. DOI: 10.3390/cimb44040107.


Hepatic Metabolism of Sakuranetin and Its Modulating Effects on Cytochrome P450s and UDP-Glucuronosyltransferases.

Jeong H, Lee J, Kim S, Yeo Y, So H, Wu H Molecules. 2018; 23(7).

PMID: 29949932 PMC: 6100415. DOI: 10.3390/molecules23071542.


Expression and prognostic value of estrogen receptor β in patients with triple-negative and triple-positive breast cancer.

Guo L, Zhu Q, Aisimutuola M, Yilamu D, Liu S, Jakulin A Exp Ther Med. 2015; 9(6):2147-2150.

PMID: 26136950 PMC: 4473352. DOI: 10.3892/etm.2015.2380.


Expression and prognostic value of estrogen receptor beta in breast cancer patients.

Guo L, Zhu Q, Yilamu D, Jakulin A, Liu S, Liang T Int J Clin Exp Med. 2014; 7(10):3730-6.

PMID: 25419426 PMC: 4238481.


Gene expression markers in circulating tumor cells may predict bone metastasis and response to hormonal treatment in breast cancer.

Wang H, Molina J, Jiang J, Ferber M, Pruthi S, Jatkoe T Mol Clin Oncol. 2014; 1(6):1031-1038.

PMID: 24649289 PMC: 3915691. DOI: 10.3892/mco.2013.163.